JILL DEBOUCHEL: Open Payments
NPI 1750651618 · CHALMETTE, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,584 in 90 payments from 10 companies in 2025. Trend: 2023 $168 · 2024 $657 · 2025 $1,584
Food & beverage: $1,584
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 50 | $763 |
| AstraZeneca Pharmaceuticals LP | 10 | $234 |
| Regeneron Healthcare Solutions, Inc. | 12 | $203 |
| GENZYME CORPORATION | 8 | $154 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 4 | $79 |
| Novo Nordisk Inc | 2 | $58 |
| Globus Medical, Inc. | 1 | $39 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $19 |
| Tris Pharma Inc | 1 | $19 |
| Lundbeck LLC | 1 | $17 |
Products named: DUPIXENT, VRAYLAR, UBRELVY, QULIPTA, BREZTRI, AIRSUPRA, CAPLYTA, Wegovy.
Industry payments across LA — which companies pay providers there.
